Aurinia Pharmaceuticals Inc — Earnings Quality Grade F
AUPH · Healthcare
Major red flags
Screening Summary
Management Signals
Source: SEC EDGAR 8-K Item 5.02, with exhibit links when available
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 53 days, change -3 days YoY
AR growth 13.4% vs revenue growth 20.4%
Revenue 20.4%, CFFO 205.6%. Cash follows revenue
Expense Quality
Inventory 16.5% vs COGS 15.6%. Normal
CapEx growth -10.3% vs revenue 20.4%. Normal
SG&A/Gross Profit = 40.7%. Normal
Gross margin 88.5%, change +0.5pp. Stable
Cash Flow Quality
CFFO/NI = 0.47. Only 47% of profit backed by cash
FCF $0.1B, FCF/NI = 0.47
Accruals ratio = 20.2%. Exceeds 10%
Cash $0.4B covers debt $0.1B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 1% of equity. Manageable
Debt/EBITDA = 0.5x. Healthy
Other assets -88.7% vs revenue 20.4%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -14% YoY. Normal
Manipulation Score
M-Score = 8.64 (> -1.78). LIKELY MANIPULATOR
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25